REG - Renalytix PLC - Director/PDMR dealings

RenalytixAnnouncement

11/12/2024 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241211:nRSK7163Pa&default-theme=true

RNS Number : 7163P  Renalytix PLC  11 December 2024

 

Renalytix plc

("Renalytix" or the "Company")

 

Director/PDMR dealings

 

LONDON and NEW YORK, 11 December 2024 - Renalytix plc (LSE: RENX) (OTCQB:
RNLXY), an artificial intelligence-enabled in vitro diagnostics company,
focused on optimizing clinical management of kidney disease to drive improved
patient outcomes and advance value-based care, announces the following
Director dealings.

 

On 5 December, certain investment vehicles connected with Christopher Mills,
Non-Executive Chairman, sold 48,601 ordinary shares of £0.0025 each
("Ordinary Shares") in the Company at a price of £0.07 per Ordinary Share on
behalf of a private client account. Following this transaction, Christopher
Mills and the investment vehicles connected with him are interested in
14,561,345 Ordinary Shares representing 4.4% of the issued share capital of
the Company.

 

On 10 December, James McCullough, Chief Executive Officer, bought 25,000
ordinary shares of £0.0025 each ("Ordinary Shares") in the Company at a price
of £0.085 per Ordinary Share. Following this transaction, James McCullough is
interested in 3,242,096 Ordinary Shares representing 0.98% of the issued share
capital of the Company.

 

Howard Doran, President of Renalytix, bought 50,000 ordinary shares of
£0.0025 each ("Ordinary Shares") in the Company at a price of £0.089 per
Ordinary Share. Following this transaction, Howard Doran is interested
in 100,000 Ordinary Shares representing 0.03% of the issued share capital of
the Company.

 

Julian Baines, Executive Chairman of Renalytix, also bought 23,000 ordinary
shares of £0.0025 each ("Ordinary Shares") in the Company at a price of
£0.085 per Ordinary Share. Following this transaction, Julian Baines is
interested in 1,848,700 Ordinary Shares representing 0.56% of the issued
share capital of the Company.

 

 

For further information, please contact:

 

 Renalytix plc                                www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                        Via Walbrook PR

 Stifel (Nominated Adviser and Joint Broker)  Tel: 020 7710 7600
 Nicholas Moore / Nick Harland / Ben Good

 Oberon Capital (Joint Broker)                Tel: 020 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited                          Tel: 020 7933 8780 or renalytix@walbrookpr.com
 Paul McManus / Alice Woodings                Mob: 07980 541 893 / 07407 804 654

 CapComm Partners
 Peter DeNardo                                Tel: 415-389-6400 or investors@renalytix.com

About Renalytix

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an in-vitro diagnostics and laboratory
services company that is the global founder and leader in the new field of
bioprognosis™ for kidney health. The leadership team, with a combined 200+
years of healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment for rapid
progressive decline in kidney function in adult patients with T2D and early
CKD (stages 1-3). We believe that by understanding how disease will progress,
patients and providers can take action early to improve outcomes and reduce
overall health system costs. For more information, visit www.renalytix.com
(http://www.renalytix.com)

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Harwood Capital LLP*

 2    Reason for the notification

 a)   Position/status                                              Christopher Mills, Non-Executive Chairman, Chief Investment Officer of Harwood

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Renalytix plc

 b)   LEI                                                          213800NTOH3FK3WER551

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.0025 each

      Identification code                                          GB00BYWL4Y04

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                         Price(s)              Volume(s)
                                                                                         £0.07                 48,601

 d)   Aggregated information

      - Aggregated volume                                          48,601
      - Price                                                      £0.07

 e)   Date of the transaction                                      5 December 2024

 f)   Place of the transaction                                     London Stock Exchange, AIM

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         James McCullough

 2    Reason for the notification

 a)   Position/status                                              CEO

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Renalytix plc

 b)   LEI                                                          213800NTOH3FK3WER551

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.0025 each

      Identification code                                          GB00BYWL4Y04

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     £0.085            25,000

 d)   Aggregated information

      - Aggregated volume                                          25,000
      - Price                                                      £0.085

 e)   Date of the transaction                                      10 December 2024

 f)   Place of the transaction                                     London Stock Exchange, AIM

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Howard Doran

 2    Reason for the notification

 a)   Position/status                                              President of Renalytix

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Renalytix plc

 b)   LEI                                                          213800NTOH3FK3WER551

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.0025 each

      Identification code                                          GB00BYWL4Y04

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     £0.089            50,000

 d)   Aggregated information

      - Aggregated volume                                          50,000
      - Price                                                      £0.089

 e)   Date of the transaction                                      10 December 2024

 f)   Place of the transaction                                     London Stock Exchange, AIM

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Julain Baines

 2    Reason for the notification

 a)   Position/status                                              Executive Chairman

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Renalytix plc

 b)   LEI                                                          213800NTOH3FK3WER551

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.0025 each

      Identification code                                          GB00BYWL4Y04

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     £0.085            23,000

 d)   Aggregated information

      - Aggregated volume                                          23,000
      - Price                                                      £0.085

 e)   Date of the transaction                                      10 December 2024

 f)   Place of the transaction                                     London Stock Exchange, AIM

 

*Christopher Mills is partner and Chief Investment Officer of Harwood Capital
LLP. Harwood Capital LLP is Investment Manager to North Atlantic Smaller
Companies Investment Trust plc and investment adviser to Oryx International
Growth Fund Limited. Christopher's shareholding is made up of ordinary shares
held by North Atlantic Smaller Companies Investment Trust PLC, Oryx
International Growth Fund Limited and Harwood Capital LLP.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBBBDDDSBDGSB